Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T22:56:03.896Z Has data issue: false hasContentIssue false

Chapter 12 - Diagnosis and management of heart disease in the elderly

from Section III - Care of the elderly by organ system

Published online by Cambridge University Press:  05 June 2016

By
Michael W. Rich  and
Joshua M. Stolker
Edited by
Jan Busby-Whitehead ,
Christine Arenson ,
Samuel C. Durso ,
Daniel Swagerty ,
Laura Mosqueda ,
Maria Fiatarone Singh  and
William Reichel
Jan Busby-Whitehead
Affiliation:
University of North Carolina
Christine Arenson
Affiliation:
Thomas Jefferson University, Philadelphia
Samuel C. Durso
Affiliation:
The Johns Hopkins University School of Medicine
Daniel Swagerty
Affiliation:
University of Kansas
Laura Mosqueda
Affiliation:
University of Southern California
Maria Fiatarone Singh
Affiliation:
University of Sydney
William Reichel
Affiliation:
Georgetown University, Washington DC
Get access

Summary

The incidence and prevalence of cardiovascular disease (CVD) increase progressively with age, and CVD is the leading cause of death and major disability in older adults. Aging affects cardiovascular structure and function. Common acute and chronic cardiovascular disorders affecting older adults include coronary artery disease, heart failure, valvular heart disease, and heart rhythm disorders. Because older adults with CVD comprise a markedly heterogeneous population, management must be individualized, with due consideration given to comorbidities, physical and cognitive function, and personal preferences regarding short-term and long-term goals of care.
Type
Chapter
Information
Reichel's Care of the Elderly
Clinical Aspects of Aging
 , pp. 157 - 186
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Moran, AE, Forouzanfar, MH, Roth, GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980–2010: the Global Burden of Disease 2010 Study. Circulation 2014;129:1483–1492.Google Scholar
Lozano, R, Naghavi, M, Foreman, K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–2128.CrossRefGoogle ScholarPubMed
Go, AS, Mozaffarian, D, Roger, VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014;129(3):399–410.Google Scholar
Lakatta, EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Failure Reviews 2002;7:29–49.CrossRefGoogle ScholarPubMed
Rich, MW. Heart disease in the elderly. In: Rosendorff, C, ed. Essential Cardiology: Principles and Practice, Third Edition. New York: Springer, 2013:669–686.Google Scholar
D’Agostino, RB, Vasan, RS, Pencina, MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–753.Google Scholar
Haffner, SM, Lehto, S, Ronnemaa, T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339:229–234.CrossRefGoogle ScholarPubMed
Kuller, LH, Arnold, AM, Psaty, BM, et al. Ten-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. Arch Int Med 2006;166:71–78.Google Scholar
White, HD, Barbash, GI, Califf, RM, et al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial. Circulation 1996;94:1826–1833.Google Scholar
Scirica, BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol 2010;55:1403–1415.CrossRefGoogle ScholarPubMed
Eggers, KM, Venge, P, Lindahl, B, Lind, L. Cardiac troponin I levels measured with a high-sensitivity assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol 2013;61:1906–1913.Google Scholar
Thygesen, K, Alpert, JS, Jaffe, AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581–1598.CrossRefGoogle ScholarPubMed
O’Gara, PT, Kushner, FG, Ascheim, DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol 2013;61:e78–140.Google Scholar
Amsterdam, EA, Wenger, NK, Brindis, RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes. J Am Coll Cardiol 2014;64(24):e139–e228.Google Scholar
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;332: 349–360.Google Scholar
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345: 494–502.CrossRefGoogle Scholar
Wiviott, SD, Braunwald, E, McCabe, CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.Google Scholar
Wallentin, L, Becker, RC, Budaj, A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.Google Scholar
Steen, H, James, S, Becker, RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012;680–688.Google Scholar
Mauri, L, Kereiakes, DJ, Yeh, RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155–2166.Google Scholar
Morrow, DA, Braunwald, E, Bonaca, MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404–1413.CrossRefGoogle ScholarPubMed
The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339: 436–443.CrossRefGoogle Scholar
Antman, EM, Cohen, M, Radley, D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602–1608.Google Scholar
FRagmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354: 701–707.Google Scholar
Dewilde, WJ, Oirbans, T, Verheugt, FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet 2013;381:1107–1115.Google Scholar
COMMIT Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622–1632.CrossRefGoogle Scholar
ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202–2212.CrossRefGoogle Scholar
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115–1122.Google Scholar
Ambrosioni, E, Borghi, C, Magnani, B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80–85.Google Scholar
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828.Google Scholar
Dickstein, K, Kjekshus, J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752–760.Google Scholar
Pitt, B, Remme, W, Zannad, F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.Google Scholar
Miettinen, TA, Pyorala, K, Olsson, AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211–4218.Google Scholar
Lewis, SJ, Moye, LA, Sacks, FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681–689.Google Scholar
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.CrossRefGoogle Scholar
Shepherd, J, Blauw, GJ, Murphy, MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–1630.Google Scholar
Stone, NJ, Intwala, S, Katz, D. Statins in very elderly adults. J Am Geriatr Soc 2014;62:943–945.Google Scholar
Rich, MW. Aggressive lipid management in very elderly adults: less is more. J Am Geriatr Soc 2014;62:945–947.Google Scholar
Sathasivam, S. Statin induced myopathy. BMJ 2008;337:a2286.CrossRefGoogle ScholarPubMed
Lee, DS, Markwardt, S, Goeres, L, et al. Statins and physical activity in older men: the osteoporotic fractures in men study. JAMA Intern Med 2014;174:1263–1270.Google Scholar
Golomb, BA, Evans, MA, Dimsdale, JE, et al. Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial. Arch Intern Med 2012;172:1180–1182.Google Scholar
Evans, MA, Golomb, BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009;29:800–811.Google Scholar
The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621–1628.Google Scholar
De Boer, MJ, Ottervanger, JP, van’t Hof, AW, et al. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002;39:1723–1728.Google Scholar
Antman, EM, Cohen, M, Bernink, PJLM, et al. The TIMI Risk Score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835–842.Google Scholar
Granger, CB, Goldberg, RJ, Dabbous, O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events (GRACE). Arch Intern Med 2003;163:2345–2353.Google Scholar
FRagmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354: 708–715.Google Scholar
Hochman, JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003;107:2998–3002.CrossRefGoogle ScholarPubMed
Hochman, JS, Sleeper, LA, White, HD, et al. for the SHOCK Investigators. One-year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190–192.CrossRefGoogle ScholarPubMed
Dzavik, V, Sleeper, LA, Cocke, TP, et al. for the SHOCK Investigators. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J 2003;24:828–837.Google Scholar
Bueno, H, Lopez-Palop, R, Perez-David, E, et al. Combined effect of age and right ventricular involvement on acute inferior myocardial infarction prognosis. Circulation 1998;98:1714–1720.Google Scholar
Hasdai, D, Topol, EJ, Califf, RM, et al. Cardiogenic shock complicating acute coronary syndromes. Lancet 2000;356:749–756.Google Scholar
Fihn, SD, Gardin, JM, Abrams, J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol 2012;60:e44–e164.Google Scholar
James, PA, Oparil, S, Carter, BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. JAMA 2014;311:507–520.Google Scholar
Stone, NJ, Robinson, JG, Lichtenstein, AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol 2014;63:2889–2934.Google Scholar
American Geriatrics Society Expert Panel on the Care of Older Adults with Diabetes Mellitus. Guidelines abstracted from the American Geriatrics Society guidelines for improving the care of older adults with diabetes mellitus: 2013 update. J Am Geriatrc Soc 2013;61:2020–2026.Google Scholar
Witt, BJ, Jacobsen, SJ, Weston, SA, et al. Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol 2004;44:988–996.Google Scholar
American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guidelines update for exercise testing. Circulation 2002;106:1883–1892.Google Scholar
The TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001;358:951–957.CrossRefGoogle Scholar
Boden, WE, O’Rourke, RA, Teo, KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503–1516.Google Scholar
Weintraub, WS, Veledar, E, Thompson, T, Burnette, J, Jurkovitz, C, Mahoney, E. Percutaneous coronary intervention outcomes in octogenarians during the stent era (National Cardiovascular Network). Am J Cardiol 2001;88:1407–1410.Google Scholar
Alexander, KP, Anstrom, KJ, Muhlbaier, LH, et al. Outcomes of cardiac surgery in patients ≥80 years: results from the National Cardiovascular Network. J Am Coll Cardiol 2000;35:731–738.CrossRefGoogle ScholarPubMed
Newman, MF, Kirchner, JL, Phillips-Bute, B, et al. for the Neurological Outcome Research Groups and the Cardiothoracic Anesthesiology Research Endeavors Investigators. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 2001;344:395–402.CrossRefGoogle ScholarPubMed
Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure. Circulation 2013;128:e240–e327.Google Scholar
The ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997.CrossRefGoogle Scholar
Moser, M, Hebert, PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214–1218.CrossRefGoogle ScholarPubMed
Okin, PM, Devereux, RB, Jern, S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343–2349.Google Scholar
Goldman, L, Hashimoto, B, Cook, EF, Loscalzo, A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981;64:1227–1234.Google Scholar
Maisel, AS, Krishnaswamy, P, Nowak, RM, et al. for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161–167.Google Scholar
Gaggin, HK, Mohammed, AA, Bhardwaj, A, et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: Results from the Prospective, Randomized ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT Study). J Cardiac Fail 2012;18:626–634.Google Scholar
Redfield, MM, Rodeheffer, RJ, Jacobsen, SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976–982.Google Scholar
Wang, TJ, Larson, MG, Levy, D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254–258.CrossRefGoogle ScholarPubMed
Heiat, A, Gross, CP, Krumholz, HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002;162:1682–1688.Google Scholar
Rich, MW, Beckham, V, Wittenberg, C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190–1195.Google Scholar
Whellan, DJ, Hasselblad, V, Peterson, E, O’Connor, CM, Schulman, KA. Meta-analysis and review of heart failure disease management randomized controlled clinical trials. Am Heart J 2005;149:722–729.Google Scholar
Ades, PA, Keteyian, SJ, Balady, GJ, et al. Cardiac rehabilitation exercise and self-care for chronic heart failure. J Am Coll Cardiol HF 2013;1(6):540–547.Google Scholar
Faris, R, Flather, M, Purcell, H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149–158.Google Scholar
Domanski, M, Norman, J, Pitt, B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705–708.Google Scholar
Neuberg, GW, Miller, AB, O’Connor, CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31–38.Google Scholar
Gheorghiade, M, Zannad, F, Sopko, G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958–3968.CrossRefGoogle ScholarPubMed
Gupta, D, Georgiopoulou, VV, Kalogeropoulos, AP, et al. Dietary sodium intake in heart failure. Circulation 2012;126:479–485.Google Scholar
Flather, MD, Yusuf, S, Kober, L, et al. for the ACEI-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACEI-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575–1581.Google Scholar
Garg, R, Yusuf, S for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450–1456.CrossRefGoogle ScholarPubMed
The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992;327:685–691.Google Scholar
Maggioni, AP, Anand, I, Gottlieb, SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414–1421.Google Scholar
Granger, CB, McMurray, JJV, Yusuf, S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–776.CrossRefGoogle ScholarPubMed
Pfeffer, MA, Swedberg, K, Granger, CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–766.CrossRefGoogle ScholarPubMed
Kuenzli, A, Bucher, HC, Anand, I, et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PloS One 2010;5:e9946.Google Scholar
Cohn, JN, Archibald, DG, Ziesche, S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547–1552.Google Scholar
Cohn, JN, Johnson, G, Ziesche, S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303–310.CrossRefGoogle ScholarPubMed
Taylor, AL, Ziesche, S, Yancy, C, et al. for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–2057.Google Scholar
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–2007.Google Scholar
Packer, M, Coats, AJS, Fowler, MB, et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.Google Scholar
Deedwania, PC, Gottlieb, S, Ghali, JK, et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004;25:1300–1309.Google Scholar
Pitt, B, Zannad, F, Remme, WJ, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709–717.Google Scholar
Zannad, F, McMurray, JJV, Krum, H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.Google Scholar
Juurlink, DN, Mamdani, MM, Lee, DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543–551.Google Scholar
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533.Google Scholar
Rich, MW, McSherry, F, Williford, WO, Yusuf, S, for the Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001;38:806–813.Google Scholar
Ahmed, A, Rich, MW, Love, TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178–186.Google Scholar
Massie, BN, Collins, JF, Ammon, SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial. Circulation 2009;119:1616–1624.CrossRefGoogle ScholarPubMed
Homma, S, Thompson, JLP, Pullicino, PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859–1869.Google Scholar
O’Connor, CM, Gattis, WA, Uretsky, BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138:78–86.Google Scholar
Cuffe, MS, Califf, RM, Adams, KFJ, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541–1547.Google Scholar
Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531–1540.Google Scholar
O’Connor, CM, Starling, RC, Hernandez, AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32–43.Google Scholar
Daneshvar, DA, Czer, LS, Phan, A, Trento, A, Schwarz, ER. Heart transplantation in the elderly: why cardiac transplantation does not need to be limited to younger patients but can be safely performed in patients above 65 years of age. Ann Transplant 2010;15:110–119.Google Scholar
Atluri, P, Goldstone, AB, Kobrin, DM, et al. Ventricular assist device implant in the elderly is associated with increased, but respectable risk: A multi-institutional study. Ann Thorac Surg 2013;96:141–147.Google Scholar
Kitzman, DW, Gardin, JM, Gottdiener, JS, et al. for the Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. Am J Cardiol 2001;87:413–419.Google Scholar
Owan, TE, Hodge, DO, Herges, RM, Jacobsen, SJ, Roger, VL, Redfield, MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–259.Google Scholar
Bhatia, RS, Tu, JV, Lee, DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. New Engl J Med 2006;355:260–269.Google Scholar
Owan, TE, Hodge, DO, Herges, RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New Engl J Med 2006;355:251–259.Google Scholar
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2011; doi:10.1093/eurheartj/ehr254.Google Scholar
Yusuf, S, Pfeffer, MA, Swedberg, K, et al. for the CHARM investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781.Google Scholar
Ahmed, A, Rich, MW, Fleg, JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group Trial. Circulation 2006;114:397–403.Google Scholar
Cleland, JGF, Tendera, M, Adamus, J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338–2345.Google Scholar
Massie, BM, Carson, PE, McMurray, JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456–2467.Google Scholar
Van Veldhuisen, DJ, Cohen-Solal, A, Bohm, M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am Coll Cardiol 2009;53:2150–2158.Google Scholar
Pitt, B, Pfeffer, MA, Assmann, SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–1392.Google Scholar
Edelmann, F, Wachter, R, Schmidt, AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013;309:781–791.Google Scholar
Redfield, MM, Chen, HH, Borlaug, BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309:1268–1277.Google Scholar
Zile, MR, Bourge, RC, Redfield, MM, Zhou, D, Baicu, CF, Little, WC. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. J Am Coll Cardiol HF 2014;2:123–130.Google Scholar
Conraads, VM, Metra, M, Kamp, O, et al. Effects of long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012;14:219–225.Google Scholar
Bristow, MR, Saxon, LA, Boehmer, J, et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150.Google Scholar
Cleland, JGF, Daubert, JC, Erdmann, E, et al. for the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med 2005;352:1539–1549.Google Scholar
Tracy, CM, Epstein, AE, Darbar, D, et al. 2012 ACCF/AHA/HRS Focused update incorporated into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation 2013;127:e283–e352.Google Scholar
Cheng, YJ, Zhang, J, Li, WJ, et al. More favorable response to cardiac resynchronization therapy in women than in men. Circ Arrhythm Electrophysiol 2014;7(5):807–815.Google Scholar
Zusterzeel, R, Selzman, KA, Sanders, WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014;174:1340–1348.Google Scholar
Verbrugge, FH, Dupont, M, De Vusser, P, et al. Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians. Eur J Heart Fail 2013;15:203–210.Google Scholar
Moss, AJ, Zareba, W, Hall, WJ, et al. for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.Google Scholar
Bardy, GH, Lee, KL, Mark, DB, et al. for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237.Google Scholar
Santangeli, P, Di Biase, L, Dello Russo, A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med 2010;153:592–599.Google Scholar
Lampert, R, Hayes, DL, Annas, GJ, et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010;7:1008–1026.Google Scholar
Feltner, C, Jones, CD, Cene, CW, et al. Transitional care interventions to reduce readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med 2014;160:774–784.Google Scholar
Huynh, BC, Rovner, A, Rich, MW. Long-term survival in elderly patients hospitalized for heart failure: 14 year follow-up from a prospective randomized trial. Arch Intern Med 2006;166:1892–1898.Google Scholar
Whellan, DJ, Goodlin, SJ, Dickinson, MG, et al. End-of-life care in patients with heart failure. J Cardiac Failure 2014;20:121–134.Google Scholar
Otto, CM, Prendergast, B. Aortic-valve stenosis – from patients at risk to severe valve obstruction. N Engl J Med 2014;371:744–756.Google Scholar
Nishimura, RA, Otto, CM, Bonow, RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Am Coll Cardiol 2014;63:e57–e185.Google Scholar
Leon, MB, Smith, CR, Mack, M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597–1607.Google Scholar
Smith, CR, Leon, MB, Mack, MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187–2198.Google Scholar
Kodali, SK, Williams, MR, Smith, CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686–1695.Google Scholar
Reynolds, MR, Magnuson, EA, Lei, Y, et al. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation 2011;124:1964–1972.Google Scholar
Lindman, BR, Alexander, KP, O’Gara, PT, Afilalo, J. Futility, benefit, and transcatheter aortic valve replacement. J Am Coll Cardiol Cardiovasc Intervent; 2014;7:707–716.Google Scholar
Scognamiglio, R, Rahimtoola, SH, Fasoli, G, et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 1994;331:689–694.Google Scholar
Evangelista, A, Tornos, P, Sambola, A, et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005;353:1342–1349.Google Scholar
Mathew, JP, Fontes, ML, Tudor, IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720–1729.Google Scholar
Crystal, E, Connolly, SJ, Sleik, K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002;106:75–80.Google Scholar
Mitchell, LB, Exner, DV, Wyse, DG, et al. Prophylactic oral amiodarone for the prevention of arrhythmias that begin early after revascularization, valve replacement, or repair – PAPABEAR: a randomized controlled trial. JAMA 2005;294:3093–3100.Google Scholar
Enriquez-Sarano, M, Avierinos, JF, Messika-Zeitoun, D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005;352:875–883.Google Scholar
Feldman, T, Foster, E, Glower, DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395–1406.Google Scholar
Wan, B, Rahnvavardi, M, Tian, DH, et al. A meta-analysis of MitraClip system versus surgery for treatment of severe mitral regurgitation. Ann Cardiothorac Surg 2013;2:683–692.Google Scholar
Lamas, GA, Lee, KL, Silverman, R, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 2002;346:1854–1862.Google Scholar
Go, AS, Hylek, EM, Phillips, KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. JAMA 2001;285:2370–2375.Google Scholar
January, CT, Wann, LS, Alpert, JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 2014;64(21):e1–e76.Google Scholar
Coleman, CI, Perkerson, KA, Gillespie, EL, et al. Impact of prophylactic beta blockade on post-cardiothoracic surgery length of stay and atrial fibrillation. Ann Phamacother 2004;38:2012–2016.Google Scholar
Kluger, J, White, CM. Amiodarone prevents symptomatic atrial fibrillation and reduces the risk of cerebrovascular events and ventricular tachycardia after open heart surgery: results of the Atrial Fibrillation Suppression Trial (AFIST). Card Electrophysiol Rev 2003;7:165–167.Google Scholar
Wyse, DG, Waldo, AL, DiMarco, JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–1833.Google Scholar
The AFFIRM Investigators. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:112–120.Google Scholar
Wolf, PA, Abbott, RD, Kannel, WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–988.Google Scholar
Gage, BF, Waterman, AD, Shannon, W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–2870.Google Scholar
Lip, GY, Nieuwlaat, R, Pisters, R, Lane, DA, Crijns, HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–72.Google Scholar
Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151.Google Scholar
Patel, MR, Mahaffey, KW, Garg, J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.Google Scholar
Granger, CB, Alexander, JH, McMurray, JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.CrossRefGoogle ScholarPubMed
Pisters, R, Lane, DA, Nieuwlaat, R, Vos, CB, Crijns, HJ, Lip, GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093–1100.Google Scholar
Lane, DA, Lip, GYH. Clinician update: use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012;126:860–865.Google Scholar
Gage, BF, Birman-Deych, E, Kerzner, R, Radford, MJ, Nilasena, DS, Rich, MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005;118:612–617.Google Scholar
Donze, J, Clair, C, Hug, B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012;125:773–778.Google Scholar
Sardar, P, Chatterjee, S, Chaudhari, S, Lip, GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014;62:857–864.Google Scholar
Buxton, AE, Lee, KL, Fisher, JD, et al. for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882–1890.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×